This inventor holds 4 USPTO granted patents and 1 published patent application. Top assignee: Onyx Pharmaceuticals, Inc.. Active years: 2000-2010.
Company Filing History:
Years Active: 2000-2010
Title: Innovations by Julie Nye in Cancer Treatment
Introduction
Julie Nye is a prominent inventor based in Berkeley, CA, who has made significant contributions to the field of cancer treatment through her innovative research. With a total of 4 patents to her name, she has focused on developing adenoviral mutants that enhance the efficacy of cancer therapies.
Latest Patents
One of her latest patents is titled "Adenovirus E1B-55K single amino acid mutants and methods of use." This patent describes adenoviral mutants that possess single amino acid mutations in the E1B-55K protein. These mutations affect the p53 binding and inactivation, as well as the late functions of the E1B-55K protein. The modifications enhance the efficacy of these viruses for treating cancer compared to adenoviral mutants that have the E1B-55K region deleted. Another significant patent is "Adenovirus E1B shuttle vectors," which provides replication competent, recombinant adenovirus vectors containing mutations in the E1B region. These vectors allow for the easy deletion of a gene or genes and the substitution of a heterologous gene that exhibits the temporal expression pattern of the deleted E1B region gene(s). Such vectors have promising applications for the treatment of neoplastic diseases.
Career Highlights
Julie Nye has been instrumental in advancing cancer treatment methodologies through her innovative work at Onyx Pharmaceuticals, Inc. Her research has paved the way for new therapeutic strategies that leverage adenoviral vectors to target cancer cells more effectively.
Collaborations
Throughout her career, Julie has collaborated with notable colleagues, including Terry Hermiston and Yuqiao Shen. These partnerships have further enriched her research and contributed to the development of her patented technologies.
Conclusion
Julie Nye's contributions to cancer treatment through her innovative patents highlight her role as a leading inventor in the field. Her work continues to inspire advancements in therapeutic strategies that could significantly impact patient care.